New treatments for multiple sclerosis: A clinical perspective

Current Opinion in Neurology

Volumn 9, Issue 3, 1996, Pages 187-198

  Thompson, Alan J ^a   Noseworthy, John H ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; BETA1 INTERFERON; CLADRIBINE; GINKGOLIDE B; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; RECOMBINANT BETA INTERFERON; ROQUINIMEX; SALAZOSULFAPYRIDINE;

CARDIOTOXICITY; CHEMOPROPHYLAXIS; DISEASE COURSE; DYSPNEA; HEART PALPITATION; HUMAN; HYPERBARIC OXYGEN; IMMUNOPATHOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE IRRADIATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; RECURRENCE RISK; REMISSION; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX PAIN;

EID: 0029900099     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199606000-00006     Document Type: Review

References (82)

1. •].
2. Wolinsky JS: Copolymer-1: a most reasonable alternative therapy • for early relapsing-remltting multiple sclerosis with mild disability [Editorial]. Neurology 1995, 45:1245-1247. The definitive copolymer report and the accompanying editorial from one of the major investigators, support the idea that Cop 1 alters the short-term natural history of relapsing-remitting MS, particularly in patients who are only mildly disabled.
3. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI •• Analysis Group: Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995, 45:1277-1385. This paper completes the clinical and MRI analysis for the Multicenter Interfon Beta-1B trial (including the extension study). The clinical and MRI benefit was maintained. An important protein with the development of neutralizing antibodies, however, has now been recognized.
4. Jacobs L: New perspectives in the treatment of MS: results with recom• binant interferon beta-la [abstract]. J Neuroimmunol 1995, (suppl 1):14. The full report of this trial is anxiously awaited.
5. Whitaker JN, McFarland HF, Rudge R, Reingold SC: Outcomes assess•• ment in multiple sclerosis clinical trials: a critical analysis. MS 1995, 1:37-47. Superb summary of the major factors to be considered in MS clinical trial design as of February 1994.
6. Polman CH, Hartung HP: The treatment of multiple sclerosis: current and future. Curr Opin Neurol 1995, 8:200-209.
7. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Doughty MM, • Schwetz KM, Fischer J, Van-Dyke C: Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30-40. A small, phase two trial suggesting possible reduction in the progression of upper limb dysfunction with methotrexate in patients with progressive MS.
8. Hobart JC, Lamping D, Thompson AJ: Evaluating outcome measures: the • bare essentials. J Neurol Neurosurg Psychiatry 1996, 60:127-130. A thoughtful review of the issues underlying outcome-based research.
9. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S et al.: Clinical outcomes assessments in multiple sclerosis. Ann Neurol 1996 (In press).
10. Panitch H: Prospects for combined immunotherapy in multiple sclerosis [Abstract]. J Neuroimmunol 1995, 15(suppl1):15.
11. Milo R, Panitch H: Additive effects of copolymer-1 and interferon beta 1-b on the immune response to myelin basic protein. J Neuroimmunol 1995, 61:185-193.
12. Alonso K, Medenica R: Immunomodulation in the treatment of multiple • sclerosis and amyotrophlc lateral sclerosis: a model for autoimmune disorders. J Nat Med Assoc 1995, 87:561-568. An uncritical, enthusiastic paper claiming combination immunotherapy may be beneficial in MS.
13. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: • results of an international survey. Neurology 1996 (In press). Consensus definitions on MS clinical course.
14. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley PED, McDonald WI: Major differences in the dynamics of primary and secondary progresslve multiple sclerosis. Ann Neurol 1991, 29:53-62.
15. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, •• Paty DW, Reingold SC, Simon J: Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996, 39:6-16. An important recent position statement providing guidelines for future clinical trial design.
16. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH: Quan•• titative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995, 118:1601-1612. One of a series of papers from the European group (MAGNIMS) discussing one aspect of longitudinal MR monitoring.
17. Sibley WA, Ebers GC, Panitch HS, Reder AT, van der Noort S: Interferon beta treatment of multiple sclerosis. Reply. Neurology 1994, 44:188-190.
18. Lublin FD, Whitaker JN, Eidleman BH, Miller AE, Amason BGW, Burks JS: •• Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996, 46:12-18. There is much useful information in this consensus statement to assist the practitioner in the day-to-day management of patients receiving interferon beta-1b.
19. Anonymous: Interferon beta-1b: hope or hype? Drug Therapeutics Bull 1996, 34:9-11.
20. Stone LA, Frank JA, Albert PS, Bush C, Smith ME, Maloni H, McFarland HF: •• The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance Imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995, 37:611-619. A prospective, open-label study showing convincing evidence that interferon beta 1-b reduces the development of gadolinium enhancing lesions with monthly MRI scanning in patients with relapsing-remitting MS.
21. Fieschi C: Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis [Abstract]. J Neuroimmunol 1995, 14(suppl 1):14.
22. Gasperini C, Koudriatseva T, Pozzilli C, Bastianello S, Colleluori A, Galgani S, Paolillo A, Gragnani F, Bozzao L, Fieschi C: Association of high dose of steroid with recombinant beta interferon therapy: prolonged effect on Gd-enhancing leslons in relapsing-remitting MS [Abstract]. J Neuroimmunol 1995, (suppl 1):35.
23. Cohen JA, Grossman RI, Udupa JK, Samarasekera S, Miki Y, Hait H, Grossman M, Constantinescu CS, Kolson DL: Assessment of the efficacy of copolymer-1 in the treatment of MS by quantitative MRI. J Neuroimmunol 1995, (suppl 1):31.
24. Johnson KP, and the US Phase III Copolymer 1 Study Group: Copolymer 1: multicentre multiple sclerosis trial extension shows Improved effects on relapse rate and disability. Ann Neurol 1995, 38:973.
25. Johnson KP, and the US Phase III Copolymer 1 Study Group: Antibodies to copolymer 1 do not interfere with its clinical effect [Abstract]. Ann Neurol 1995, 38:973.
26. Poehlau D, Amoiridis G, Postert T, Schimrigk S, Nastos I, Schoeis L, Przuntek H: Intravenous lmmunoglobulin (IVIg) for the treatment of progressive multiple sclerosis (MS) [Abstract]. J Neuroimmunol 1995, (suppl 1):47.
27. Achiron A, Cohen IR, Lider O, Melamed E: Intravenous immunoglobulin treatment in multiple sclerosis. Israel J Med Sci 1995, 31:7-9.
28. Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon C, Noy S, Sarova-Pinhas I, Melamed E: Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992, 49:1233-1236.
29. Achiron A, Gilad R, Hassin S, Barak Y, Gabbay U, Ziv Y1 Goldhamer E, Melamed E, Sarova-Pinhas I: Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: a randomized, double-blind multicenter, placebo-controlled trial [abstract]. J Neuroimmunol 1995, (suppl 1):15.
30. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R: Intravenous immunoglobulin treatment in the prevention of childblrth-associated acute exacerations in multiple sclerosis - a pilot study [abstract]. J Neuroimmunol 1995, (suppl 1):56
31. Rodriguez M, Lennon VA: Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990, 27:12-17.
32. van Engelen BGM, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M: Promotion of remyelination by polyclonal immunoglobulin and IVIg in Theiler's virus induced demyelination and in MS. J Neurol Neurosurg Psychiatry 1994, 57(suppl 1):65-68.
33. Noseworthy JH, O'Brien PC, van Engelen BGM, Rodriguez M: Intravenous lmmunoglobulin therapy in multiple sclerosis: progress from the Theiler's virus model to a randomized, double-blinded, placebo-controlled clinical trial J Neurol Neurosurg Psychiatry 1994, 57(suppl):11-14.
34. Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, Churchill WH Jr: Plasmapheresls in fulminant acute disseminated encephalomyelitis. Neurology 1995, 45:824-827.
35. Rechtner KM, Baum K: Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatments with plasmapheresis. J Neurol Sci 1994, 126:146-148.
36. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA: Plasmapharesis in acute episodes of fulminant CNS inflammatory demyellnation. Neurology 1993, 43:1100-1104.
37. Sorenson PS, Wanscher B, Szpirt W, Jensen CV, Ravnborg M, Christiansen P, Nordenbo A: A controlled trial of plasma exchange in multiple sclerosis using serial MRI and multimodal evoked potentials as efficacy parameters. J Neuroimmunol 1995, (suppl 1):74.
38. Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH: Serial gadolinium-enhanced magnetic resonance Imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiol 1995, 37:113-119.
39. Kappos L: Mitoxantone (Mx) in the treatment of rapidly progressive multiple sclerosis. A pilot study with serial gadolinium (Gd)-enhanced MRI [abstract]. Neurology 1990, 40(suppl 1):261.
40. Gonsette RE: Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients [Abstract]. Neurology 1990, 40(suppl 1):261.
41. Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman M, Rice GPA, Grinwich KD, Cauvier H, Harris BJ, Ebers GC: An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993, 43:1401-1406.
42. De Castro S, Cartoni D, Millefiorini E, Funaro S, Gasperini C, Morino S, Tallanco D, Beni S: Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995, 35:627-632.
43. Millefiorini E, Gasperini C, and the Mitoxantrone Italian Study Group: Randomized double-blind, placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24 months clinical and MRI results [Abstract]. J Neuroimmunol 1995, (suppl 1):16.
44. Edan G, Rennes C, and the French and British Multiple Sclerosis Mitoxantrone Trial Group: Demonstration of the efficacy of mitoxantrone (MTX) MRI in MS patients with a very active disease [abstract]. J Neuroimmunol 1995, (suppl 1):16.
45. Kappos L, Radu EW, Haas J, Hartard CH, Hartung HP: European multicentre trial +/- deoxyspergualine (DSG) versus placebo: results of the first interim analysis. J Neurol 1994, 241 (suppl 1):S27.
46. Kappos L, Radu EW, Haas J, Hartard CH, Hartung HP and the DSG Study Group: Deoxyspergualine in MS: a second interim analysis of the European multicentre study. J Neurol 1995, 242(suppl 2):S23.
47. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyruff J, Beutler E: Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994, 344:9-13.
48. •].
49. •] showing an apparent short-term benefit in MRI behavior from Linomide compared with placebo in patients with active, relapsing-remitting and secondary-progressive MS.
50. Cook SD, Devereux C, Troiano R, Hafstein MP, Zito G, Hernandez E, Lavenhar M, Vidaver R, Dowling PC: Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet 1986, 1:1405-1409.
51. Cook SD, Devereux C, Troiano R, Bansil S, Zito G, Sheffet A, Jolkowitz A, Rohowsky-Kochen C, Dowling PC: Combination total lymphoid irradiation and low-dose corticosteroid therapy for progressive multiple sclerosis. Acta Neurol Scand 1995, 91-.22-27.
52. Wiles CM, Omar L, Swan AV, Swan G, Frankel J, Grunewald R, Joannides T, Jones P, Laing H, Richardson PH et al: Total lymphoid irradiation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994, 57:154-163.
53. Kleijnen J, Knipschild P: Hyperbaric oxygen for multiple sclerosis: review • of controlled trlals. Acta Neurol Scand 1995, 91:330-334. A sensible critique of studies in this area.
54. Fischer BH, Marks M, Reich T: Hyperbaric oxygen treatment of multiple sclerosis. A randomlsed, placebo-controlled, double-blind study. N Engl J Med 1983, 308:181-186.
55. Brochet B, Orgogozo JM, Guinot P, Dartigues JF, Henry P, Loiseau P: Pilot study of ginkgollde B, a PAF-acether speclfic inhibitor in the treatment of acute outbreaks of multiple sclerosis (In French). Revue Neurologique 1992, 148:299-301.
56. Brochet B, Guinot P, Orgogozo JM, Confauvreux C, Rumbach L, Lavergne V: Double-blind placebo-controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. J Neurol Neurosurg Psychiatry 1995, 58:360-362.
57. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldman H, Clayton D, Wing M, Scolding N, Compston A: Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994, 344:298-301.
58. Miller DH, Lai HM, Lewellyn-Smith N, Cuzner L, McDonald WI: Phase 2 trlal of anti-CD4 antibodies in the treatment of multiple sclerosis. J Neurol 1995. 242(suppl 2):S23.
59. Weiner HL, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafter DA: Oral tolerance: immunologic mechanisms and treatment of animal and human organspecific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol 1994, 12:809-837.
60. Shellenberger MK, Wallace JD, and the U.S. Tizanidine Advisory Group: Extended efficacy of tizanldine in the treatment of patients with multiple sclerosis (MS) [Abstract]. Neurology 1995, 45(suppl 4):683P.
61. Nguyen JP, Pollin B, Feve A, Geny C, Ricolfi F, Niclof P, Degos J-D, Cesaro P: • Treatment of severe tremor by chronic thalmlc stimulation in 25 patients with multiple sclerosis. J Nauroimmunol 1995, (suppl 1):30. A potentially valuable approach for carefully selected patients with the most disabling of symptoms.
62. Averbuch-Heller L, Stahl JS, Rottach KG, Leigh RJ: Gabapentin as treatment for nystagmus. Ann Neurol 1995, 38:972.
63. Reder AT, Amason BGW: Trigemlnal nerualgla in multiple sclerosis relleved by a prostoglandin E analogue. Neurology 1995, 45:1097-1100.
64. Khan OA, Olek MJ: Treatment of paroxysmal symptoms in multiple sclerosis with bromocrlptine. J Neurol Neurosurg Psychiatry 1995, 58:253.
65. Fowler CJ: Investigation of the neurogenic bladder. J Neurol Neurosurg • Psychiatry 1996, 60:6-13. An authoritative and comprehensive review of topic.
66. Eckford SD, Carter PG, Jackson SR, Penney MD, Abrams P: An open in-patient incremental safety efficacy study of desmopressln in women with multiple sclerosis and nocturia. Br J Urol 1995, 74:459-463.
67. Mattson D, Petrie M, Stivastava DK, McDermott M: Multiple sclerosis: sexual dysfunction and its response to medications. Arch Neurol 1995, 52:862-868.
68. Chia Y-W, Fowler CJ, Kamm MA, Henry MM, Lemieux M-C, Swash M: Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 1995, 242:105-108.
69. Betts CD, Jones SJ, Fowler CG, Fowler CJ: Erectile dysfunction in multiple sclerosis: associated neurological and neurophysiological deficits and treatment of the condition. Brain 1994, 117:1303-1310.
70. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, • Johnson B, Morgante L, Grimson R: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995, 45:1956-1961. A useful if somewhat negative study.
71. Bever CT, Young D, Tiemey D, Conway K, Katz E, Costello K, Fossler M, Johnson KP: The pharmocokinetics and tolerability of a slow release formulation of 4-aminopyridine in multiple sclerosis patients. Neurology 1995, 45(suppl 4):A351.
72. Thompson AJ: Neurorehabilitation for people with multiple sclerosis. In Proceedings of the MS forum: psychosocial factors in multiple sclerosis. Modem Management Workshop, Rome. Proceedings of the MS Forum 9-12 April 1995 .
73. Stolp-Smith KA, Atkinson EJ, O'Brien PC, Rodriguez M: Rehabilitation service utilization in the multiple sclerosis prevalence cohort in Olmsted County, MN. Ann Neurol 1995, 38:345.
74. Rossiter D, Thompson AJ: The introduction of integrated care pathways for patients with multiple sclerosis in an inpatient neurorehabilitation setting. Disab Rehab 1995, 17:443-448.
75. Kidd D, Howard RS, Losseff NA, Thompson AJ: The benefit of inpatient neurorehabilitation in multiple sclerosis. Clin Rehab 1995, 9:198-203.
76. Vickery BG, Hays RD, Harooni R, Myers LW, Kendall BE, Moseley IF, Thompson AJ, Keir G, Miller DH, Feldmann M, Thompson EJ: A healthrelated quality of life measure for multiple sclerosis. Quality of Life Res 1995, 4: 187-206.
77. Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Moseley IF, Thompson AJ, Keir G, Miller DH, Feldmann M, Thompson EJ: Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 60: 20-26.
78. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, Pflughaupt KW, Toyka KV: Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995, 38:186-193.
79. Canella B, Raine CS: The adhesion molecule and cytokine profile of • multiple sclerosis lesions. Ann Neurol 1995. 37:424-435. This paper compared the expression of a panel of adhesion and cylokine molecules within central nervous system tissue from subjects with and without MS. While not revealing any pattern peculiar to MS they did demonstrate greater usage of the vascular cell adhesion molecule-1/very late activation antigen-4 pathway in older lesions when compared with acute lesions.
80. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Horner HC: Monoclonal antibody to alpha 4 integren suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995, 58:1-10.
81. Racke MK, Critchfield JM, Quigley L, Cannella B, Raine CS, McFarland HF, •• Lenardo MJ: Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Ann Neurol 1996;39:46-56. The authors suggest that frequent injections of myelin basic protein are required to suppress activity in EAE but that this is effective even in chronic disease and in the absence of exogenous interleukin-2.
82. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, Martin R, Utz U, Kann N, Mitchell D et al.: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996, 379:343-346.